Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.
Future Cardiol
; 5(2): 159-73, 2009 Mar.
Article
en En
| MEDLINE
| ID: mdl-19371190
ABSTRACT
Lipoprotein-associated phospholipase A2 (Lp-PLA2), present in the circulation and in atherosclerotic plaque, is an inflammatory marker with potential use as a predictor of cardiovascular risk and as a therapeutic target. Although Lp-PLA2 is associated with both LDL and HDL, it is important to determine whether Lp-PLA2 has a predominantly pro- or anti-atherogenic effect. Increasing evidence suggests a proatherogenic role for Lp-PLA2. Epidemiologic and clinical evidence suggests Lp-PLA2 is an independent predictor of risk and may be superior to other inflammatory markers owing to its specificity and minimal biovariation. Lp-PLA2 inhibitors currently being investigated in clinical trials are promising novel anti-inflammatory agents with a specificity for the vascular bed and a potential for decreasing plaque vulnerability.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Cardiovasculares
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
1-Alquil-2-acetilglicerofosfocolina Esterasa
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Future Cardiol
Asunto de la revista:
CARDIOLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Estados Unidos